Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311068 | 0.92 | UCHL1 (0.49) | ESR2UCHL1MAPK1NR1H2DDB1 | |
| SCHEMBL3304095 | 0.88 | NR1D1 (0.42) | ESR2UCHL1MAPK1NR1H2TMEM97 | |
| SCHEMBL1570606 | 0.83 | ESR2 (0.54) | ESR2UCHL1MAPK1NR1H2TMEM97 | |
| SCHEMBL29801280 | 0.83 | ESR2 (0.54) | ESR2UCHL1MAPK1NR1H2TMEM97 | |
| SCHEMBL14904850 | 0.80 | ESR2 (0.47) | ESR2UCHL1MAPK1NR1H2TMEM97 | |
| SCHEMBL3309743 | 0.80 | UCHL1 (0.44) | ESR2UCHL1MAPK1NR1H2DDB1 | |
| SCHEMBL25107642 | 0.80 | ESR2 (0.51) | ESR2UCHL1MAPK1NR1H2TMEM97 | |
| SCHEMBL14895889 | 0.79 | ESR2 (0.53) | ESR2UCHL1MAPK1NR1H2TMEM97 | |
| SCHEMBL19739032 | 0.77 | ESR2 (0.51) | ESR2UCHL1MAPK1NR1H2TMEM97 | |
| SCHEMBL14868188 | 0.76 | ESR2 (0.50) | ESR2UCHL1MAPK1NR1H2TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | ESR2 663/4885UCHL1 4176/4885MAPK1 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.